-
Electronic (PDF)
-
Site License
-
Enterprisewide
HIV / AIDS - Pipeline Review, H2 2012
Global Markets Direct, August 2012, Pages: 445
HIV / AIDS – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'HIV / AIDS - Pipeline Review, H2 2012', provides an overview of the HIV / AIDS therapeutic pipeline. This report provides information on the therapeutic development for HIV / AIDS, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV / AIDS. 'HIV / AIDS - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for HIV / AIDS.
- A review of the HIV / AIDS products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the HIV / AIDS pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for HIV / AIDS.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding HIV / AIDS pipeline depth and focus of HIV / AIDS therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
HIV / AIDS Therapeutic Products under Development, Key Players in HIV / AIDS Therapeutics, HIV / AIDS Pipeline Overview, HIV / AIDS Pipeline, HIV / AIDS Pipeline Assessment
2
List of Tables 8
List of Figures 13
Introduction 14
REPORT COVERAGE 14
HIV / AIDS Overview 15
Therapeutics Development 16
An Overview of Pipeline Products for HIV / AIDS 16
HIV / AIDS Therapeutics under Development by Companies 18
HIV / AIDS Therapeutics under Investigation by Universities/Institutes 28
Late Stage Products 34
Comparative Analysis 34
Mid Clinical Stage Products 35
Comparative Analysis 35
Early Clinical Stage Products 36
Comparative Analysis 36
Discovery and Pre-Clinical Stage Products 37
Comparative Analysis 37
HIV / AIDS Therapeutics – Products under Development by Companies 38
HIV / AIDS Therapeutics – Products under Investigation by Universities/Institutes 51
Companies Involved in HIV / AIDS Therapeutics Development 68
Bristol-Myers Squibb Company 68
Johnson & Johnson 69
Abbott Laboratories 70
Vical Incorporated 71
Shionogi & Co., Ltd. 72
GlaxoSmithKline plc 73
Nektar Therapeutics 74
Inovio Biomedical Corporation 75
Gilead Sciences, Inc. 76
VIRxSYS Corporation 77
Merck & Co., Inc. 78
United Biomedical, Inc. 79
Lentigen Corporation 80
Myriad Genetics, Inc. 81
Sangamo BioSciences, Inc. 82
Cytokine PharmaSciences, Inc. 83
Generex Biotechnology Corporation 84
Ceragenix Pharmaceuticals, Inc. 85
Nanotherapeutics, Inc. 86
Ambrilia Biopharma Inc. 87
Panacos Pharmaceuticals, Inc. 88
Biotron Limited 89
Aphios Corporation 90
Achillion Pharmaceuticals, Inc. 91
Esteve Group 92
Japan Tobacco Inc. 93
Pfizer Inc. 94
SuperGen, Inc. 95
Hadasit Medical Research Services & Development Ltd 96
Avexa Limited 97
Koronis Pharmaceuticals, Inc. 98
Alfacell Corporation 99
Geron Corporation 100
GeoVax Labs, Inc. 101
Hemispherx Biopharma, Inc. 102
Celldex Therapeutics, Inc. 103
iCo Therapeutics Inc. 104
Enzo Biochem, Inc. 105
Ardea Biosciences, Inc. 106
Medivir AB 107
Bio-Bridge Science, Inc. 108
Mymetics Corporation 109
NanoViricides, Inc. 110
Nutra Pharma Corporation 111
ConjuChem Biotechnologies Inc. 112
Critical Outcome Technologies Inc. 113
CytoGenix, Inc. 114
ADVENTRX Pharmaceuticals 115
Starpharma Holdings Limited 116
Immuron Limited 117
Samaritan Pharmaceuticals, Inc. 118
Takara Bio Inc. 119
BioAlliance Pharma SA 120
Transgene Biotek Ltd 121
Paloma Pharmaceuticals, Inc. 122
Antigen Express, Inc. 123
Functional Genetics, Inc. 124
BioClonetics Incorporated 125
Nutri Pharma ASA 126
Pharmaplaz Ltd. 127
BioMAS Ltd. 128
Vironova AB 129
ViroStatics, srl 130
Argos Therapeutics, Inc. 131
Cytheris SA 132
Altor BioScience Corporation 133
PX’Therapeutics SA 134
Osel Inc. 135
Heat Biologics, Inc. 136
AiCuris GmbH & Co. KG 137
AlphaVax, Inc. 138
Indus Biotech Private Limited 139
Locus Pharmaceuticals, Inc. 140
Presidio Pharmaceuticals, Inc. 141
Theraclone Sciences, Inc. 142
Frontier Biotechnologies, Inc. 143
Kainos Medicine, Inc. 144
Viral Genetics, Inc. 145
Concert Pharmaceuticals, Inc. 146
Myriad Pharmaceuticals, Inc. 147
CytoDyn, Inc. 148
GeneCure LLC 149
Omeros Corporation 150
Oncolys BioPharma Inc. 151
Globeimmune, Inc. 152
Etubics Corporation 153
Immunocore Limited. 154
Canopus BioPharma Incorporated 155
Discovery Genomics, Inc. 156
PepTcell Limited 157
Arisyn Therapeutics Inc. 158
TVAX Biomedical, LLC 159
Tobira Therapeutics, Inc. 160
Genetic Immunity, LLC 161
TNI Pharmaceuticals, Inc. 162
GenPhar, Inc. 163
Medisyn Technologies, Inc. 164
Napo Pharmaceuticals, Inc. 165
Pharis Biotec GmbH 166
Immunomic Therapeutics, Inc. 167
GeoVax, Inc. 168
Heptares Therapeutics Ltd. 169
VIRIOM Ltd. 170
CONRAD 171
ViiV Healthcare 172
RFS Pharma, LLC 173
Helix Therapeutics LLC 174
Vichem Chemie Research Ltd. 175
ImQuest Life Sciences 176
HIV / AIDS – Therapeutics Assessment 177
Assessment by Monotherapy Products 177
Assessment by Combination Products 178
Assessment by Route of Administration 179
Assessment by Molecule Type 181
Drug Profiles 183
Cobicistat - Drug Profile 183
1349572 - Drug Profile 184
Crofelemer - Drug Profile 186
Crofelemer - Drug Profile 188
JTK-303 - Drug Profile 190
JTK-303 - Drug Profile 193
SP-01A - Drug Profile 196
Ampligen - Drug Profile 198
Apricitabine - Drug Profile 199
Quad - Drug Profile 200
Tenofovir + Emtricitabine + Efavirenz - Drug Profile 202
Dapivirine Ring - Drug Profile 204
Emtricitabine + Tenofovir Disoproxil Fumarate - Drug Profile 206
Zidovudine + Lamivudine + Nevirapine - Drug Profile 207
Zidovudine + Lamivudine + Efavirenz - Drug Profile 208
Aluvia - Drug Profile 210
Aluvia + Raltegravir - Drug Profile 211
Nevirapine - Drug Profile 213
Emtricitabine + Tenofovir Disoproxil Fumarate + Lopinavir + Ritonavir + Nevirapine - Drug Profile 214
Proleukin + Anti-HIV Therapy - Drug Profile 216
Emtricitabine + Tenofovir Disoproxil Fumarate + Ritonavir + Atazanavir - Drug Profile 218
Emtricitabine + Tenofovir Disoproxil Fumarate + Raltegravir - Drug Profile 219
Emtricitabine + Tenofovir Disoproxil Fumarate + Darunavir + Ritonavir - Drug Profile 220
Erythromycin + Nevirapine + Ampicillin Sodium + Metronidazole - Drug Profile 222
Valacyclovir - Drug Profile 224
Buprenorphine + Naloxone - Drug Profile 226
Prednisone - Drug Profile 227
Raltegravir + Truvada - Drug Profile 228
Stavudine + Lamivudine + Abacavir - Drug Profile 229
Emtricitabine + Tenofovir - Drug Profile 230
Tenofovir - Drug Profile 231
Stavudine + Lamivudine + Nevirapine - Drug Profile 232
Abacavir + Lamivudine + Nevirapine - Drug Profile 233
Zidovudine + Lamivudine + Abacavir - Drug Profile 235
GPO-VIR S + GPO-VIR Z - Drug Profile 236
GPO-VIR Z - Drug Profile 238
Truvada + Nevirapine - Drug Profile 239
Didanosine + Abacavir + Kaletra - Drug Profile 240
Zidovudine + Lamivudine + Kaletra - Drug Profile 242
Proleukin + Paracetamol + Ibuprofen + Ondansetron + Codeine Phosphate - Drug Profile 244
Proleukin + Paracetamol + Ibuprofen + Metoclopramide + Codeine Phosphate - Drug Profile 246
Isentress + Kaletra - Drug Profile 248
Stavudine + Lamivudine + Nevirapine - Drug Profile 249
Stavudine + Lamivudine + Efavirenz - Drug Profile 251
Abacavir + Lamivudine + Nevirapine - Drug Profile 253
Abacavir + Lamivudine + Efavirenz - Drug Profile 255
Zidovudine + Lamivudine + Nevirapine - Drug Profile 257
Zidovudine + Lamivudine + Efavirenz - Drug Profile 259
Lopinavir + Ritonavir + Zidovudine - Drug Profile 261
Remune - Drug Profile 262
Zidovudine + Nevirapine - Drug Profile 264
Zidovudine - Drug Profile 266
Indinavir + Ritonavir + Abacavir + Didanosine + Proleukin - Drug Profile 267
Darunavir + Ritonavir - Drug Profile 269
Tenofovir Disoproxil Fumarate - Drug Profile 270
Tenofovir + Emtricitabine + Efavirenz - Drug Profile 272
Isentress + Celsentri + Prezista + Norvir + Truvada - Drug Profile 274
Sustiva + Epzicom - Drug Profile 276
Atazanavir + Ritonavir + Abacavir + Lamivudine - Drug Profile 277
Lamivudine + Zidovudine + Nelfinavir + Efavirenz - Drug Profile 279
Nevirapine + Lopinavir + Ritonavir - Drug Profile 281
Ritonavir + Saquinavir + Efavirenz - Drug Profile 282
Ziodovudine + Alpha Interferon - Drug Profile 284
Kaletra - Drug Profile 285
Atazanavir + Emtricitabine + Tenofovir Disoproxil Fumarate + Ritonavir - Drug Profile 287
Enfuvirtide + Raltegravir + Darunavir + Tipranavir + Etravirine + Maraviroc - Drug Profile 289
Abacavir + Lamivudine + Atazanavir + Ritonavir - Drug Profile 291
Abacavir Sulfate + Didanosine + Efavirenz + Lamivudine + Lopinavir + Nevirapine + Zidovudine - Drug Profile 293
Lopinavir + Ritonavir + Nucleoside Reverse Transcriptase Inhibitors + PEG-IFNa 2a + Ribavirin - Drug Profile 295
Raltegravir + Maraviroc + Tenofovir + Emtricitabine - Drug Profile 297
Viread + Aluvia - Drug Profile 299
Truvada + Nevirapine - Drug Profile 301
Truvada + Zidovudine - Drug Profile 303
Truvada - Drug Profile 305
Abacavir + Lamivudine + Efavirenz - Drug Profile 306
Darunavir + Ritonavir + Raltegravir - Drug Profile 308
Atazanavir + Didanosine + Efavirexnz + Emtricitabine + Tenofovir Disoproxil Fumarate + Lamivudine + Lopinavir + Ritonavir + Nevirapine + Stavudine + Zidovudine - Drug Profile 309
Raltegravir + Maraviroc + Emtricitabine + Tenofovir + Lopinavir + Ritonavir - Drug Profile 312
Lopinavir + Ritonavir - Drug Profile 314
Darunavir + Ritonavir - Drug Profile 315
Isentress + Celsentri + Truvada + Kaletra - Drug Profile 316
Truvada + Raltegravir - Drug Profile 318
Fuzeon + Truvada + Kaletra - Drug Profile 320
Abacavir - Drug Profile 322
Abacavir + Lamivudine + Efavirenz - Drug Profile 323
Efavirenz - Drug Profile 324
Etravirine - Drug Profile 325
Tenofovir - Drug Profile 326
Celsentri + Antiretroviral Therapy - Drug Profile 328
Lamivudine + Tenofovir + Atazanavir + Ritonavir - Drug Profile 330
572-Trii - Drug Profile 332
Reyataz + Cobicistat - Drug Profile 334
Cobicistat + Prezista - Drug Profile 336
Pentamidine - Drug Profile 337
RemuneX - Drug Profile 338
Atazanavir + Lamivudine + Ritonavir - Drug Profile 340
HIV / AIDS Therapeutics – Drug Profile Updates 341
HIV / AIDS Therapeutics – Discontinued Products 361
HIV / AIDS Therapeutics - Dormant Products 370
HIV / AIDS – Product Development Milestones 426
Featured News & Press Releases 426
Appendix 437
Methodology 437
Coverage 437
Secondary Research 437
Primary Research 437
Expert Panel Validation 437
Contact Us 438
Disclaimer 438
List of Tables
Number of Products Under Development for HIV / AIDS, H2 2012 23
Products under Development for HIV / AIDS – Comparative Analysis, H2 2012 24
Number of Products under Development by Companies, H2 2012 26
Number of Products under Development by Companies, H2 2012 (Contd..1) 27
Number of Products under Development by Companies, H2 2012 (Contd..2) 28
Number of Products under Development by Companies, H2 2012 (Contd..3) 29
Number of Products under Development by Companies, H2 2012 (Contd..4) 30
Number of Products under Development by Companies, H2 2012 (Contd..5) 31
Number of Products under Development by Companies, H2 2012 (Contd..6) 32
Number of Products under Development by Companies, H2 2012 (Contd..7) 33
Number of Products under Development by Companies, H2 2012 (Contd..8) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 38
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 39
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 40
Comparative Analysis by Late Stage Development, H2 2012 41
Comparative Analysis by Mid Clinical Stage Development, H2 2012 42
Comparative Analysis by Early Clinical Stage Development, H2 2012 43
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 44
Products under Development by Companies, H2 2012 45
Products under Development by Companies, H2 2012 (Contd..1) 46
Products under Development by Companies, H2 2012 (Contd..2) 47
Products under Development by Companies, H2 2012 (Contd..3) 48
Products under Development by Companies, H2 2012 (Contd..4) 49
Products under Development by Companies, H2 2012 (Contd..5) 50
Products under Development by Companies, H2 2012 (Contd..6) 51
Products under Development by Companies, H2 2012 (Contd..7) 52
Products under Development by Companies, H2 2012 (Contd..8) 53
Products under Development by Companies, H2 2012 (Contd..9) 54
Products under Development by Companies, H2 2012 (Contd..10) 55
Products under Development by Companies, H2 2012 (Contd..11) 56
Products under Development by Companies, H2 2012 (Contd..12) 57
Products under Investigation by Universities/Institutes, H2 2012 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 64
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 65
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 67
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 68
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 69
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 70
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 71
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 72
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 73
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 74
Bristol-Myers Squibb Company, H2 2012 75
Johnson & Johnson, H2 2012 76
Abbott Laboratories, H2 2012 77
Vical Incorporated, H2 2012 78
Shionogi & Co., Ltd., H2 2012 79
GlaxoSmithKline plc, H2 2012 80
Nektar Therapeutics, H2 2012 81
Inovio Biomedical Corporation, H2 2012 82
Gilead Sciences, Inc., H2 2012 83
VIRxSYS Corporation, H2 2012 84
Merck & Co., Inc., H2 2012 85
United Biomedical, Inc., H2 2012 86
Lentigen Corporation, H2 2012 87
Myriad Genetics, Inc., H2 2012 88
Sangamo BioSciences, Inc., H2 2012 89
Cytokine PharmaSciences, Inc., H2 2012 90
Generex Biotechnology Corporation, H2 2012 91
Ceragenix Pharmaceuticals, Inc., H2 2012 92
Nanotherapeutics, Inc., H2 2012 93
Ambrilia Biopharma Inc., H2 2012 94
Panacos Pharmaceuticals, Inc., H2 2012 95
Biotron Limited, H2 2012 96
Aphios Corporation, H2 2012 97
Achillion Pharmaceuticals, Inc., H2 2012 98
Esteve Group, H2 2012 99
Japan Tobacco Inc., H2 2012 100
Pfizer Inc., H2 2012 101
SuperGen, Inc., H2 2012 102
Hadasit Medical Research Services & Development Ltd, H2 2012 103
Avexa Limited, H2 2012 104
Koronis Pharmaceuticals, Inc., H2 2012 105
Alfacell Corporation, H2 2012 106
Geron Corporation, H2 2012 107
GeoVax Labs, Inc., H2 2012 108
Hemispherx Biopharma, Inc., H2 2012 109
Celldex Therapeutics, Inc., H2 2012 110
iCo Therapeutics Inc., H2 2012 111
Enzo Biochem, Inc., H2 2012 112
Ardea Biosciences, Inc., H2 2012 113
Medivir AB, H2 2012 114
Bio-Bridge Science, Inc., H2 2012 115
Mymetics Corporation, H2 2012 116
NanoViricides, Inc., H2 2012 117
Nutra Pharma Corporation, H2 2012 118
ConjuChem Biotechnologies Inc., H2 2012 119
Critical Outcome Technologies Inc., H2 2012 120
CytoGenix, Inc., H2 2012 121
ADVENTRX Pharmaceuticals, H2 2012 122
Starpharma Holdings Limited, H2 2012 123
Immuron Limited, H2 2012 124
Samaritan Pharmaceuticals, Inc., H2 2012 125
Takara Bio Inc., H2 2012 126
BioAlliance Pharma SA, H2 2012 127
Transgene Biotek Ltd, H2 2012 128
Paloma Pharmaceuticals, Inc., H2 2012 129
Antigen Express, Inc., H2 2012 130
Functional Genetics, Inc., H2 2012 131
BioClonetics Incorporated, H2 2012 132
Nutri Pharma ASA, H2 2012 133
Pharmaplaz Ltd., H2 2012 134
BioMAS Ltd., H2 2012 135
Vironova AB, H2 2012 136
ViroStatics, srl, H2 2012 137
Argos Therapeutics, Inc., H2 2012 138
Cytheris SA, H2 2012 139
Altor BioScience Corporation, H2 2012 140
PX’Therapeutics SA, H2 2012 141
Osel Inc., H2 2012 142
Heat Biologics, Inc., H2 2012 143
AiCuris GmbH & Co. KG, H2 2012 144
AlphaVax, Inc., H2 2012 145
Indus Biotech Private Limited, H2 2012 146
Locus Pharmaceuticals, Inc., H2 2012 147
Presidio Pharmaceuticals, Inc., H2 2012 148
Theraclone Sciences, Inc., H2 2012 149
Frontier Biotechnologies, Inc., H2 2012 150
Kainos Medicine, Inc., H2 2012 151
Viral Genetics, Inc., H2 2012 152
Concert Pharmaceuticals, Inc., H2 2012 153
Myriad Pharmaceuticals, Inc., H2 2012 154
CytoDyn, Inc., H2 2012 155
GeneCure LLC, H2 2012 156
Omeros Corporation, H2 2012 157
Oncolys BioPharma Inc., H2 2012 158
Globeimmune, Inc., H2 2012 159
Etubics Corporation, H2 2012 160
Immunocore Limited., H2 2012 161
Canopus BioPharma Incorporated, H2 2012 162
Discovery Genomics, Inc., H2 2012 163
PepTcell Limited, H2 2012 164
Arisyn Therapeutics Inc., H2 2012 165
TVAX Biomedical, LLC, H2 2012 166
Tobira Therapeutics, Inc., H2 2012 167
Genetic Immunity, LLC, H2 2012 168
TNI Pharmaceuticals, Inc., H2 2012 169
GenPhar, Inc., H2 2012 170
Medisyn Technologies, Inc., H2 2012 171
Napo Pharmaceuticals, Inc., H2 2012 172
Pharis Biotec GmbH, H2 2012 173
Immunomic Therapeutics, Inc., H2 2012 174
GeoVax, Inc., H2 2012 175
Heptares Therapeutics Ltd., H2 2012 176
VIRIOM Ltd., H2 2012 177
CONRAD, H2 2012 178
ViiV Healthcare, H2 2012 179
RFS Pharma, LLC, H2 2012 180
Helix Therapeutics LLC, H2 2012 181
Vichem Chemie Research Ltd., H2 2012 182
ImQuest Life Sciences, H2 2012 183
Assessment by Monotherapy Products, H2 2012 184
Assessment by Combination Products, H2 2012 185
Assessment by Stage and Route of Administration, H2 2012 187
Assessment by Stage and Molecule Type, H2 2012 189
HIV / AIDS Therapeutics – Drug Profile Updates 348
HIV / AIDS Therapeutics – Discontinued Products 368
HIV / AIDS Therapeutics – Discontinued Products (Contd..1) 369
HIV / AIDS Therapeutics – Discontinued Products (Contd..2) 370
HIV / AIDS Therapeutics – Discontinued Products (Contd..3) 371
HIV / AIDS Therapeutics – Discontinued Products (Contd..4) 372
HIV / AIDS Therapeutics – Discontinued Products (Contd..5) 373
HIV / AIDS Therapeutics – Discontinued Products (Contd..6) 374
HIV / AIDS Therapeutics – Discontinued Products (Contd..7) 375
HIV / AIDS Therapeutics – Discontinued Products (Contd..8) 376
HIV / AIDS Therapeutics – Dormant Products 377
HIV / AIDS Therapeutics – Dormant Products (Contd..1) 378
HIV / AIDS Therapeutics – Dormant Products (Contd..2) 379
HIV / AIDS Therapeutics – Dormant Products (Contd..3) 380
HIV / AIDS Therapeutics – Dormant Products (Contd..4) 381
HIV / AIDS Therapeutics – Dormant Products (Contd..5) 382
HIV / AIDS Therapeutics – Dormant Products (Contd..6) 383
HIV / AIDS Therapeutics – Dormant Products (Contd..7) 384
HIV / AIDS Therapeutics – Dormant Products (Contd..8) 385
HIV / AIDS Therapeutics – Dormant Products (Contd..9) 386
HIV / AIDS Therapeutics – Dormant Products (Contd..10) 387
HIV / AIDS Therapeutics – Dormant Products (Contd..11) 388
HIV / AIDS Therapeutics – Dormant Products (Contd..12) 389
HIV / AIDS Therapeutics – Dormant Products (Contd..13) 390
HIV / AIDS Therapeutics – Dormant Products (Contd..14) 391
HIV / AIDS Therapeutics – Dormant Products (Contd..15) 392
HIV / AIDS Therapeutics – Dormant Products (Contd..16) 393
HIV / AIDS Therapeutics – Dormant Products (Contd..17) 394
HIV / AIDS Therapeutics – Dormant Products (Contd..18) 395
HIV / AIDS Therapeutics – Dormant Products (Contd..19) 396
HIV / AIDS Therapeutics – Dormant Products (Contd..20) 397
HIV / AIDS Therapeutics – Dormant Products (Contd..21) 398
HIV / AIDS Therapeutics – Dormant Products (Contd..22) 399
HIV / AIDS Therapeutics – Dormant Products (Contd..23) 400
HIV / AIDS Therapeutics – Dormant Products (Contd..24) 401
HIV / AIDS Therapeutics – Dormant Products (Contd..25) 402
HIV / AIDS Therapeutics – Dormant Products (Contd..26) 403
HIV / AIDS Therapeutics – Dormant Products (Contd..27) 404
HIV / AIDS Therapeutics – Dormant Products (Contd..28) 405
HIV / AIDS Therapeutics – Dormant Products (Contd..29) 406
HIV / AIDS Therapeutics – Dormant Products (Contd..30) 407
HIV / AIDS Therapeutics – Dormant Products (Contd..31) 408
HIV / AIDS Therapeutics – Dormant Products (Contd..32) 409
HIV / AIDS Therapeutics – Dormant Products (Contd..33) 410
HIV / AIDS Therapeutics – Dormant Products (Contd..34) 411
HIV / AIDS Therapeutics – Dormant Products (Contd..35) 412
HIV / AIDS Therapeutics – Dormant Products (Contd..36) 413
HIV / AIDS Therapeutics – Dormant Products (Contd..37) 414
HIV / AIDS Therapeutics – Dormant Products (Contd..38) 415
HIV / AIDS Therapeutics – Dormant Products (Contd..39) 416
HIV / AIDS Therapeutics – Dormant Products (Contd..40) 417
HIV / AIDS Therapeutics – Dormant Products (Contd..41) 418
HIV / AIDS Therapeutics – Dormant Products (Contd..42) 419
HIV / AIDS Therapeutics – Dormant Products (Contd..43) 420
HIV / AIDS Therapeutics – Dormant Products (Contd..44) 421
HIV / AIDS Therapeutics – Dormant Products (Contd..45) 422
HIV / AIDS Therapeutics – Dormant Products (Contd..46) 423
HIV / AIDS Therapeutics – Dormant Products (Contd..47) 424
HIV / AIDS Therapeutics – Dormant Products (Contd..48) 425
HIV / AIDS Therapeutics – Dormant Products (Contd..49) 426
HIV / AIDS Therapeutics – Dormant Products (Contd..50) 427
HIV / AIDS Therapeutics – Dormant Products (Contd..51) 428
HIV / AIDS Therapeutics – Dormant Products (Contd..52) 429
HIV / AIDS Therapeutics – Dormant Products (Contd..53) 430
HIV / AIDS Therapeutics – Dormant Products (Contd..54) 431
HIV / AIDS Therapeutics – Dormant Products (Contd..55) 432
List of Figures
Number of Products under Development for HIV / AIDS, H2 2012 23
Products under Development for HIV / AIDS – Comparative Analysis, H2 2012 24
Products under Development by Companies, H2 2012 25
Products under Investigation by Universities/Institutes, H2 2012 35
Late Stage Products, H2 2012 41
Mid Clinical Stage Products, H2 2012 42
Early Clinical Stage Products, H2 2012 43
Discovery and Pre-Clinical Stage Products, H2 2012 44
Assessment by Monotherapy Products, H2 2012 184
Assessment by Combination Products, H2 2012 185
Assessment by Route of Administration, H2 2012 186
Assessment by Stage and Route of Administration, H2 2012 187
Assessment by Molecule Type, H2 2012 188
Assessment by Stage and Molecule Type, H2 2012 189
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
